bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 4 from EGFR Protein Expression in Non–Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor—A Novel Antibody for Immunohistochemistry or AQUA Technology
Authors: Mascaux Celine , Wynes Murry W. , Kato Yasufumi , Tran Cindy , Asuncion Bernadette Reyna , Zhao Jason M. , Gustavson Mark , Ranger-Moore Jim , Gaire Fabien , Matsubayashi Jun , Nagao Toshitaka , Yoshida Koichi , Ohira Tatuso , Ikeda Norihiko , Hirsch Fred R.
Published: April 2023

PDF file - 162KB
Related Article from “License to Kill” Reflects Joint Action of CD4 and CD8 T Cells
Authors: Melief Cornelis J.M.
Published: April 2023

Related Article from “License to Kill” Reflects Joint Action of CD4 and CD8 T Cells
Supplementary Table 3 from Genomic Estimates of Aneuploid Content in Glioblastoma Multiforme and Improved Classification
Authors: Li Bo , Senbabaoglu Yasin , Peng Weiping , Yang Min-Lee , Xu Jishu , Li Jun Z.
Published: April 2023

XLS file, 198K, Revised class assignment obtained in this work.
Supplementary Methods from Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features
Authors: Gammaitoni Loretta , Giraudo Lidia , Leuci Valeria , Todorovic Maja , Mesiano Giulia , Picciotto Franco , Pisacane Alberto , Zaccagna Alessandro , Volpe Maria Giuseppa , Gallo Susanna , Caravelli Daniela , Giacone Elena , Venesio Tiziana , Balsamo Antonella , Pignochino Ymera , Grignani Giovanni , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

PDF file - 63K
Supplementary Figure 1 from Epigenetic Alteration of PRKCDBP in Colorectal Cancers and Its Implication in Tumor Cell Resistance to TNFα-Induced Apoptosis
Authors: Lee Jin-Hee , Kang Min-Ju , Han Hye-Yeon , Lee Min-Goo , Jeong Seong-In , Ryu Byung-Kyu , Ha Tae-Kyu , Her Nam-Goo , Han Jikhyon , Park Sun Jin , Lee Kil Yeon , Kim Hyo-Jong , Chi Sung-Gil
Published: April 2023

PDF file - 50K
Supplementary Figure S4 from Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor
Authors: Álvarez-Fernández Stela , Ortiz-Ruiz María Jesús , Parrott Tracy , Zaknoen Sara , Ocio Enrique M. , San Miguel Jesús , Burrows Francis J. , Esparís-Ogando Azucena , Pandiella Atanasio
Published: April 2023

Effect of TG02 on the amount of cells in the distinct cell cycle phases.
Supplementary Figure S1 from Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor
Authors: Álvarez-Fernández Stela , Ortiz-Ruiz María Jesús , Parrott Tracy , Zaknoen Sara , Ocio Enrique M. , San Miguel Jesús , Burrows Francis J. , Esparís-Ogando Azucena , Pandiella Atanasio
Published: April 2023

Ex vivo effect of TG02 on primary myeloma cells analyzed in each of the patients separately.
Supplementary Figure 1 from IGKV3 Proteins as Candidate “Off-the-Shelf” Vaccines for Kappa-Light Chain–Restricted B-Cell Non-Hodgkin Lymphomas
Authors: Martorelli Debora , Guidoboni Massimo , De Re Valli , Muraro Elena , Turrini Riccardo , Merlo Anna , Pasini Elisa , Caggiari Laura , Romagnoli Luca , Spina Michele , Mortarini Roberta , Gasparotto Daniela , Mazzucato Mario , Carbone Antonino , Rosato Antonio , Anichini Andrea , Dolcetti Riccardo
Published: April 2023

PDF file, 303KB, Serum antibody responses to the IGKV3-20 recombinant protein in IGKV3+ lymphoma patients and healthy donors assessed by a chemiluminescence ELISA. Data are expressed as the ratio between the relative fluorescence unit (RFU) of the IGKV3-20 and those of tetanus toxoid, as reference value of antibody memory response to an exogenous antigen. This approach has been chosen to limit the possible influence of tumor-related immune suppression.
Supplementary Table 5 from PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Authors: Meric-Bernstam Funda , Akcakanat Argun , Chen Huiqin , Do Kim-Anh , Sangai Takafumi , Adkins Farrell , Gonzalez-Angulo Ana Maria , Rashid Asif , Crosby Katherine , Dong Mei , Phan Alexandria T. , Wolff Robert A. , Gupta Sanjay , Mills Gordon B. , Yao James
Published: April 2023

PDF file - 91K
Supplementary Table 3 from PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Authors: Meric-Bernstam Funda , Akcakanat Argun , Chen Huiqin , Do Kim-Anh , Sangai Takafumi , Adkins Farrell , Gonzalez-Angulo Ana Maria , Rashid Asif , Crosby Katherine , Dong Mei , Phan Alexandria T. , Wolff Robert A. , Gupta Sanjay , Mills Gordon B. , Yao James
Published: April 2023

PDF file - 90K
Supplementary Table 2 from PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Authors: Meric-Bernstam Funda , Akcakanat Argun , Chen Huiqin , Do Kim-Anh , Sangai Takafumi , Adkins Farrell , Gonzalez-Angulo Ana Maria , Rashid Asif , Crosby Katherine , Dong Mei , Phan Alexandria T. , Wolff Robert A. , Gupta Sanjay , Mills Gordon B. , Yao James
Published: April 2023

PDF file - 83K
Supplementary Table 1 from PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Authors: Meric-Bernstam Funda , Akcakanat Argun , Chen Huiqin , Do Kim-Anh , Sangai Takafumi , Adkins Farrell , Gonzalez-Angulo Ana Maria , Rashid Asif , Crosby Katherine , Dong Mei , Phan Alexandria T. , Wolff Robert A. , Gupta Sanjay , Mills Gordon B. , Yao James
Published: April 2023

PDF file - 72K
Supplementary Figure 1 from The Rectal Cancer microRNAome – microRNA Expression in Rectal Cancer and Matched Normal Mucosa
Authors: Gaedcke Jochen , Grade Marian , Camps Jordi , Søkilde Rolf , Kaczkowski Bogumil , Schetter Aaron J. , Difilippantonio Michael J. , Harris Curtis C. , Ghadimi B. Michael , Møller Søren , Beissbarth Tim , Ried Thomas , Litman Thomas
Published: April 2023

PDF file, 208K, Identfication of miR-652*.
Supplementary Methods from IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
Authors: Wainwright Derek A. , Balyasnikova Irina V. , Chang Alan L. , Ahmed Atique U. , Moon Kyung-Sub , Auffinger Brenda , Tobias Alex L. , Han Yu , Lesniak Maciej S.
Published: April 2023

PDF file, 104K.
Supplementary Figure 6 from Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence
Authors: Di Martino Maria T. , Leone Emanuela , Amodio Nicola , Foresta Umberto , Lionetti Marta , Pitari Maria R. , Cantafio Maria E. Gallo , Gullà Annamaria , Conforti Francesco , Morelli Eugenio , Tomaino Vera , Rossi Marco , Negrini Massimo , Ferrarini Manlio , Caraglia Michele , Shammas Masood A. , Munshi Nikhil C. , Anderson Kenneth C. , Neri Antonino , Tagliaferri Pierosandro , Tassone Pierfrancesco
Published: April 2023

PDF file - 111K, In vivo activity of miR-34a in RPMI-8226 xenografts
Supplementary Figure 4 from IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
Authors: Wainwright Derek A. , Balyasnikova Irina V. , Chang Alan L. , Ahmed Atique U. , Moon Kyung-Sub , Auffinger Brenda , Tobias Alex L. , Han Yu , Lesniak Maciej S.
Published: April 2023

PDF file, 78K, Analysis of GL261 IDO knockdowns.
Supplementary Methods from Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells
Authors: Fiskus Warren , Rao Rekha , Balusu Ramesh , Ganguly Siddhartha , Tao Jianguo , Sotomayor Eduardo , Mudunuru Uma , Smith Jacqueline E. , Hembruff Stacey L. , Atadja Peter , Marquez Victor E. , Bhalla Kapil
Published: April 2023

PDF file, 19K.
Supplementary Figures 1 - 5 from Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells
Authors: Fiskus Warren , Rao Rekha , Balusu Ramesh , Ganguly Siddhartha , Tao Jianguo , Sotomayor Eduardo , Mudunuru Uma , Smith Jacqueline E. , Hembruff Stacey L. , Atadja Peter , Marquez Victor E. , Bhalla Kapil
Published: April 2023

PDF file, 659K, Supplemental Figure 1. Treatment with DZNep depletes expression of PRC2 proteins in MCL MO2058 and Z-138 cells. Supplemental Figure 2. Treatment with DZNep upregulates mRNA expression of EZH2 target genes in MCL cells.A-C. Supplemental Figure 3. Treatment with DZNep does not alter hsa-miR-101 expression in MCL cells. Supplemental Figure 4. Effects of treatment with DZNep or PS in MCL Z-138 cells Supplemental Figure 5. Treatment with PS significantly enhances the anti-MCL activity of DZNep in JeKo-1 and Z-138 cells.
Supplementary Figure Legends from Accelerated Tumor Growth Mediated by Sublytic Levels of Antibody-Induced Complement Activation Is Associated with Activation of the PI3K/AKT Survival Pathway
Authors: Wu Xiaohong , Ragupathi Govind , Panageas Katherine , Hong Feng , Livingston Philip O.
Published: April 2023

Legend for supplementary figures - PDF file 62K, Supplementary Figure Legend
Supplementary Table 2 from An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Authors: Byers Lauren Averett , Diao Lixia , Wang Jing , Saintigny Pierre , Girard Luc , Peyton Michael , Shen Li , Fan Youhong , Giri Uma , Tumula Praveen K. , Nilsson Monique B. , Gudikote Jayanthi , Tran Hai , Cardnell Robert J.G. , Bearss David J. , Warner Steven L. , Foulks Jason M. , Kanner Steven B. , Gandhi Varsha , Krett Nancy , Rosen Steven T. , Kim Edward S. , Herbst Roy S. , Blumenschein George R. , Lee J. Jack , Lippman Scott M. , Ang K. Kian , Mills Gordon B. , Hong Waun K. , Weinstein John N. , Wistuba Ignacio I. , Coombes Kevin R. , Minna John D. , Heymach John V.
Published: April 2023

PDF file - 51K, EMT status of commonly mutated genes in NSCLC
Supplementary Figure 1, Tables 1-2 from IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors
Authors: Becker Marc A. , Hou Xiaonan , Harrington Sean C. , Weroha S. John , Gonzalez Sergio E. , Jacob Kristina A. , Carboni Joan M. , Gottardis Marco M. , Haluska Paul
Published: April 2023

PDF file - 2.5MB
Supplementary Figure 3 from An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Authors: Byers Lauren Averett , Diao Lixia , Wang Jing , Saintigny Pierre , Girard Luc , Peyton Michael , Shen Li , Fan Youhong , Giri Uma , Tumula Praveen K. , Nilsson Monique B. , Gudikote Jayanthi , Tran Hai , Cardnell Robert J.G. , Bearss David J. , Warner Steven L. , Foulks Jason M. , Kanner Steven B. , Gandhi Varsha , Krett Nancy , Rosen Steven T. , Kim Edward S. , Herbst Roy S. , Blumenschein George R. , Lee J. Jack , Lippman Scott M. , Ang K. Kian , Mills Gordon B. , Hong Waun K. , Weinstein John N. , Wistuba Ignacio I. , Coombes Kevin R. , Minna John D. , Heymach John V.
Published: April 2023

PDF file - 66K, CDH1 probes vary in their accuracy and dynamic range
Supplementary Figure Legend from Prolonged Inhibition of Glioblastoma Xenograft Initiation and Clonogenic Growth following In Vivo Notch Blockade
Authors: Chu Qian , Orr Brent A. , Semenkow Samantha , Bar Eli E. , Eberhart Charles G.
Published: April 2023

PDF file - 76K
Supplementary Figure 3 from Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776
Authors: Engelke Carl G. , Parsels Leslie A. , Qian Yushen , Zhang Qiang , Karnak David , Robertson Jordan R. , Tanska Daria M. , Wei Dongping , Davis Mary A. , Parsels Joshua D. , Zhao Lili , Greenson Joel K. , Lawrence Theodore S. , Maybaum Jonathan , Morgan Meredith A.
Published: April 2023

PDF file, 126K, MK8776 treatment causes persistent gammaH2AX expression in response to gemcitabine/radiation in MiaPaCa-2 but not Capan-1 cells.
Supplementary Figure 1 from Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776
Authors: Engelke Carl G. , Parsels Leslie A. , Qian Yushen , Zhang Qiang , Karnak David , Robertson Jordan R. , Tanska Daria M. , Wei Dongping , Davis Mary A. , Parsels Joshua D. , Zhao Lili , Greenson Joel K. , Lawrence Theodore S. , Maybaum Jonathan , Morgan Meredith A.
Published: April 2023

PDF file, 85K, Pancreatic cancer cell survival in response to increasing concentrations of MK8776.
Supplementary Figure 2A from A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report
Authors: Widemann Brigitte C. , Kim AeRang , Fox Elizabeth , Baruchel Sylvain , Adamson Peter C. , Ingle Ashish M. , Bender Julia Glade , Burke Michael , Weigel Brenda , Stempak Diana , Balis Frank M. , Blaney Susan M.
Published: April 2023

PDF file, 39K, Plasma soluble VEGFR2 (A) and Placental Growth Factor (B) concentrations prior to therapy (baseline) and at the end of cycle 1 (steady state).
Supplementary Table 4 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Authors: Alfonso Sailyn , Valdés-Zayas Anet , Santiesteban Eduardo R. , Flores Yoanna I. , Areces Fernando , Hernández Maurenis , Viada Carmen E. , Mendoza Ivis C. , Guerra Pedro P. , García Elena , Ortiz Ramón A. , de la Torre Ana V. , Cepeda Meylán , Pérez Kirenia , Chong Eric , Hernández Ana María , Toledo Darien , González Zuyén , Mazorra Zaima , Crombet Tania , Pérez Rolando , Vázquez Ana María , Macías Amparo E.
Published: April 2023

PDF file - 2804KB, Association of antibody response with patient's survival.
Supplementary Table 2 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Authors: Alfonso Sailyn , Valdés-Zayas Anet , Santiesteban Eduardo R. , Flores Yoanna I. , Areces Fernando , Hernández Maurenis , Viada Carmen E. , Mendoza Ivis C. , Guerra Pedro P. , García Elena , Ortiz Ramón A. , de la Torre Ana V. , Cepeda Meylán , Pérez Kirenia , Chong Eric , Hernández Ana María , Toledo Darien , González Zuyén , Mazorra Zaima , Crombet Tania , Pérez Rolando , Vázquez Ana María , Macías Amparo E.
Published: April 2023

PDF file - 66KB, Summary of adverse events.
Supplementary Tables 1 - 2 from Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis
Authors: Liu Ren , Li Xiuqing , Gao Wenming , Zhou Yue , Wey Shiuan , Mitra Satyajit K. , Krasnoperov Valery , Dong Dezheng , Liu Shuanglong , Li Dan , Zhu Genyuan , Louie Stan , Conti Peter S. , Li Zibo , Lee Amy S. , Gill Parkash S.
Published: April 2023

PDF file - 62K, Table S1. Humanized MAb159 Pharmacokinetics in mouse. Table S2. Toxicology study of humanized MAb159 in mouse.
Supplementary Methods from Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis
Authors: Liu Ren , Li Xiuqing , Gao Wenming , Zhou Yue , Wey Shiuan , Mitra Satyajit K. , Krasnoperov Valery , Dong Dezheng , Liu Shuanglong , Li Dan , Zhu Genyuan , Louie Stan , Conti Peter S. , Li Zibo , Lee Amy S. , Gill Parkash S.
Published: April 2023

PDF file - 121K
Supplementary Legends for Figures 1-5 and Tables 1-4 from TP53 Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence
Authors: Skinner Heath D. , Sandulache Vlad C. , Ow Thomas J. , Meyn Raymond E. , Yordy John S. , Beadle Beth M. , Fitzgerald Alison L. , Giri Uma , Ang K. Kian , Myers Jeffrey N.
Published: April 2023

PDF file - 100K
Related Article from In Search of a Real “Targeted” Therapy for Thyroid Cancer
Authors: Brose Marcia S.
Published: April 2023

Related Article from In Search of a Real “Targeted” Therapy for Thyroid Cancer
Supplementary Methods from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
Authors: Schwartzberg Lee S. , Tauer Kurt W. , Hermann Robert C. , Makari-Judson Grace , Isaacs Claudine , Beck J. Thaddeus , Kaklamani Virginia , Stepanski Edward J. , Rugo Hope S. , Wang Wei , Bell-McGuinn Katherine , Kirshner Jeffrey J. , Eisenberg Peter , Emanuelson Richard , Keaton Mark , Levine Ellis , Medgyesy Diana C. , Qamar Rubina , Starr Alexander , Ro Sunhee Kwon , Lokker Nathalie A. , Hudis Clifford A.
Published: April 2023

PDF file - 65K
Data Supplement from Is the “3+3” Dose-Escalation Phase I Clinical Trial Design Suitable for Therapeutic Cancer Vaccine Development? A Recommendation for Alternative Design
Authors: Rahma Osama E. , Gammoh Emily , Simon Richard M. , Khleif Samir N.
Published: April 2023

Supplemental Table 1. All analyzed trials and the range of the administered vaccine doses.
Supplementary Figure Legend from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Authors: Fanale Michelle A. , Forero-Torres Andres , Rosenblatt Joseph D. , Advani Ranjana H. , Franklin Anna R. , Kennedy Dana A. , Han Tae H. , Sievers Eric L. , Bartlett Nancy L.
Published: April 2023

PDF file - 45KB
Supplementary Table S1 from Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response
Authors: Zannella Vanessa E. , Dal Pra Alan , Muaddi Hala , McKee Trevor D. , Stapleton Shawn , Sykes Jenna , Glicksman Rachel , Chaib Selim , Zamiara Paul , Milosevic Michael , Wouters Bradly G. , Bristow Robert G. , Koritzinsky Marianne
Published: April 2023

PDF file 97K, Table S1 shows the clinical demographics of the patient cohort treated with radiotherapy for prostate cancer
Supplementary Figure from Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer
Authors: von Minckwitz Gunter , Schmitt Wolfgang D. , Loibl Sibylle , Müller Berit M. , Blohmer Jens U. , Sinn Bruno V. , Eidtmann Holger , Eiermann Wolfgang , Gerber Bernd , Tesch Hans , Hilfrich Jörn , Huober Jens , Fehm Tanja , Barinoff Jana , Rüdiger Thomas , Erbstoesser Erhard , Fasching Peter A. , Karn Thomas , Müller Volkmar , Jackisch Christian , Denkert Carsten
Published: April 2023

PDF file, 66K, Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the treatment effect of conventional versus response-guided neoadjuvant chemotherapy as measured by mean disease-free survival according to overlapping subpopulations defined by percentages of Ki67 at surgery in patients with hormone-receptor-positive (A) and hormone-receptor-negative (B) disease.
Supplementary Table 4 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma
Authors: Fouret Robert , Laffaire Julien , Hofman Paul , Beau-Faller Michèle , Mazieres Julien , Validire Pierre , Girard Philippe , Camilleri-Bröet Sophie , Vaylet Fabien , Leroy-Ladurie François , Soria Jean-Charles , Fouret Pierre
Published: April 2023

PDF file, 64K, Different characteristics between never smokers and ever smokers.
Supplementary Figure 2B from Integrated Analysis Reveals Critical Genomic Regions in Prostate Tumor Microenvironment Associated with Clinicopathologic Phenotypes
Authors: Ashida Shingo , Orloff Mohammed S. , Bebek Gurkan , Zhang Li , Zheng Pan , Peehl Donna M. , Eng Charis
Published: April 2023

PDF file - 17K
Supplementary Table 1 from Copper Chelation Enhances Antitumor Efficacy and Systemic Delivery of Oncolytic HSV
Authors: Yoo Ji Young , Pradarelli Jason , Haseley Amy , Wojton Jeffrey , Kaka Azeem , Bratasz Anna , Alvarez-Breckenridge Christopher A. , Yu Jun-Ge , Powell Kimerly , Mazar Andrew P. , Teknos Theodoros N. , Chiocca E. Antonio , Glorioso Joseph C. , Old Matthew , Kaur Balveen
Published: April 2023

PDF file, 82K.
Supplementary Figure 2 from Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors
Authors: Xin Yan , Li Jessica , Wu Jenny , Kinard Rashell , Weekes Colin D. , Patnaik Amita , LoRusso Patricia , Brachmann Rainer , Tong Raymond K. , Yan Yibing , Watts Ryan , Bai Shuang , Hegde Priti S.
Published: April 2023

PDF file, 72K, Binding experiments were carried out by surface plasmon resonance (SPR) measurements on a ProteOn XPR36 (Bio-Rad Laboratories) instrument at 25{degree sign}C. For the binding competition experiment, PlGF (20μg/ml) was immobilized at high surface densities (3000-4000 RU) on an activated ProteOn GLC sensor chip using standard amine coupling procedures as described by the manufacturer. Analytes (Nrp1, Anti-Nrp1B) and 1:1 molar ratio mixture of analytes (Nrp1 + Anti-Nrp1B) were injected in phosphate-buffered saline (PBS), 0.005% v/v Tween-20 (pH7.4) at a flow rate of 100μl/min and sensorgrams for association and disassociation phases were recorded. Analytes were injected for 150 s and allowed to disassociate for 450 s. Data was processed with the ProteOn Manager software (version 2.0, Bio-Rad).
Supplementary Table 3 from Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier
Authors: Salphati Laurent , Heffron Timothy P. , Alicke Bruno , Nishimura Merry , Barck Kai , Carano Richard A. , Cheong Jonathan , Edgar Kyle A. , Greve Joan , Kharbanda Samir , Koeppen Hartmut , Lau Shari , Lee Leslie B. , Pang Jodie , Plise Emile G. , Pokorny Jenny L. , Reslan Hani Bou , Sarkaria Jann N. , Wallin Jeffrey J. , Zhang Xiaolin , Gould Stephen E. , Olivero Alan G. , Phillips Heidi S.
Published: April 2023

PDF file - 57K, Selectivity of GNE-317 against a Panel of 59 Kinases. GNE-317 was Tested at 1 �M in the Invitrogen SelectScreen
Supplemental Figure 2 from Mesenchymal Stem Cells from Human Fat Engineered to Secrete BMP4 Are Nononcogenic, Suppress Brain Cancer, and Prolong Survival
Authors: Li Qian , Wijesekera Olindi , Salas Sussan J. , Wang Joanna Y. , Zhu Mingxin , Aprhys Colette , Chaichana Kaisorn L. , Chesler David A. , Zhang Hao , Smith Christopher L. , Guerrero-Cazares Hugo , Levchenko Andre , Quinones-Hinojosa Alfredo
Published: April 2023

Supplementary SFig. 2. hAMSCs-BMP4 decrease BTIC proliferation in vitro.
Supplementary Data from microRNA-224 Promotes Cell Proliferation and Tumor Growth in Human Colorectal Cancer by Repressing PHLPP1 and PHLPP2
Authors: Liao Wen-Ting , Li Ting-Ting , Wang Zheng-Gen , Wang Shu-Yang , He Mei-Rong , Ye Ya-Ping , Qi Lu , Cui Yan-Mei , Wu Ping , Jiao Hong-Li , Zhang Chi , Xie Yi-Jun , Wang Jun-Xian , Ding Yan-Qing
Published: April 2023

Supplementary Data - PDF file155K, Supplementary data, including Supplementary methods, Supplementary figure legends, and Supplementary Tables
Supplementary Data from Importance of 5α-Reductase Gene Polymorphisms on Circulating and Intraprostatic Androgens in Prostate Cancer
Authors: Lévesque Éric , Laverdière Isabelle , Lacombe Louis , Caron Patrick , Rouleau Mélanie , Turcotte Véronique , Têtu Bernard , Fradet Yves , Guillemette Chantal
Published: April 2023

PDF file 138K, Relationshio between sex-steroid hormone levels and molecular markers in SRD5A genes
Supplementary Figure Legends from Synergistic Anticancer Effects of Pam3CSK4 and Ara-C on B-Cell Lymphoma Cells
Authors: Lee Sae-Kyung , Chwee Jyh Y. , Ma Cheryl A.P. , Le Bert Nina , Huang Caleb W. , Gasser Stephan
Published: April 2023

PDF file - 128K
Supplementary Figure 2 from Synergistic Anticancer Effects of Pam3CSK4 and Ara-C on B-Cell Lymphoma Cells
Authors: Lee Sae-Kyung , Chwee Jyh Y. , Ma Cheryl A.P. , Le Bert Nina , Huang Caleb W. , Gasser Stephan
Published: April 2023

PDF file - 63K, Efficiency of p53 shRNA and IκBα overexpression.
Supplementary Table 2 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
Authors: Busuttil Rita A. , George Joshy , Tothill Richard W. , Ioculano Kylie , Kowalczyk Adam , Mitchell Catherine , Lade Stephen , Tan Patrick , Haviv Izhak , Boussioutas Alex
Published: April 2023

XLS file - 39KB, Genes represented in each HOPACH cluster.
Supplementary Tables 4 - 6 from Clusterin Is a Gene-Specific Target of microRNA-21 in Head and Neck Squamous Cell Carcinoma
Authors: Mydlarz Wojciech , Uemura Mamoru , Ahn Sun , Hennessey Patrick , Chang Steven , Demokan Semra , Sun Wenyue , Shao Chunbo , Bishop Justin , Krosting Julie , Mambo Elizabeth , Westra William , Ha Patrick , Sidransky David , Califano Joseph
Published: April 2023

XLSX file - 841K, Supplementary Table 4. miRNA array analysis of discovery cohort. Supplementary Table 5. miRNA array significant call signals. Supplementary Table 6. RT-qPCR validation of miRNA array.
Supplementary Table 1 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
Authors: Busuttil Rita A. , George Joshy , Tothill Richard W. , Ioculano Kylie , Kowalczyk Adam , Mitchell Catherine , Lade Stephen , Tan Patrick , Haviv Izhak , Boussioutas Alex
Published: April 2023

XLS file - 24KB, Clinical parameters of Peter Mac gastric samples.
Supplementary Materials and Methods from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
Authors: Busuttil Rita A. , George Joshy , Tothill Richard W. , Ioculano Kylie , Kowalczyk Adam , Mitchell Catherine , Lade Stephen , Tan Patrick , Haviv Izhak , Boussioutas Alex
Published: April 2023

PDF file - 81KB
Supplementary Methods from A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
Authors: Zhu Andrew X. , Finn Richard S. , Mulcahy Mary , Gurtler Jayne , Sun Weijing , Schwartz Jonathan D. , Dalal Rita P. , Joshi Adarsh , Hozak Rebecca R. , Xu Yihuan , Ancukiewicz Marek , Jain Rakesh K. , Nugent Francis W. , Duda Dan G. , Stuart Keith
Published: April 2023

PDF file - 65K
Supplementary Figure 2 from The Integrin Inhibitor Cilengitide Affects Meningioma Cell Motility and Invasion
Authors: Wilisch-Neumann Annette , Kliese Nadine , Pachow Doreen , Schneider Thomas , Warnke Jan-Peter , Braunsdorf Werner EK , Böhmer Frank-Dietmar , Hass Peter , Pasemann Diana , Helbing Cornelia , Kirches Elmar , Mawrin Christian
Published: April 2023

Supplementary Figure 2 - PDF file 128K, Cell cycle analyses under cilengitide treatment. Meningioma cell lines treated with cilengitide and analysed for cell cycle changes
Figure S3 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
Authors: McClements Lana , Yakkundi Anita , Papaspyropoulos Angelos , Harrison Hannah , Ablett Matthew P. , Jithesh Puthen V. , McKeen Hayley D. , Bennett Rachel , Donley Christopher , Kissenpfennig Adrien , McIntosh Stuart , McCarthy Helen O. , O'Neill Eric , Clarke Robert B. , Robson Tracy
Published: April 2023

Figure S3 - PDF file 26K, Figure S3. AD-01 is not cytotoxic. No change in surviving fraction following AD-01 treatment in both MDA-231 and MCF-7 cells was observed.
Figure S2 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
Authors: McClements Lana , Yakkundi Anita , Papaspyropoulos Angelos , Harrison Hannah , Ablett Matthew P. , Jithesh Puthen V. , McKeen Hayley D. , Bennett Rachel , Donley Christopher , Kissenpfennig Adrien , McIntosh Stuart , McCarthy Helen O. , O'Neill Eric , Clarke Robert B. , Robson Tracy
Published: April 2023

Figure S2 - PDF file 28K, Figure S2. MDA-231 cells treated with the gamma secretase inhibitor, compound E (E) (0.025 microM, 0.25 microM, 1.25 microM), or AD-01 (0.025 nM), alone or in combination. Data points are mean {plus minus} SEM. n{greater than or equal to}3. * p<0.05, ** p<0.01, *** p<0.001 (one-way ANOVA)
Figure S1 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
Authors: McClements Lana , Yakkundi Anita , Papaspyropoulos Angelos , Harrison Hannah , Ablett Matthew P. , Jithesh Puthen V. , McKeen Hayley D. , Bennett Rachel , Donley Christopher , Kissenpfennig Adrien , McIntosh Stuart , McCarthy Helen O. , O'Neill Eric , Clarke Robert B. , Robson Tracy
Published: April 2023

Figure S1 - PDF file 49K, Figure S1. (A) Mammosphere formation efficiency (MFE) in MDA-231 cells exposed to varying concentrations of AD-01. (B) Primary (1), secondary (2) and tertiary (3) mammosphere formation in the MDA-231 cell line following 1 nM AD-01 treatment (black bar - control; grey bar - AD-01 treatment). See Fig. 1 for further description of the methods. (C) 1 and 2 mammosphere formation in the MCF-7 cell line versus MCF-7 cells stably overexpressing FKBPL (D2). Data points are mean plus-minus SEM. n greater than or equal to 3. * p<0.05, ** p<0.01, *** p<0.001 (one-way ANOVA)
Supplementary Figure 3 from Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas
Authors: Zhao Qi , Caballero Otavia L. , Davis Ian D. , Jonasch Eric , Tamboli Pheroze , Yung W.K. Alfred , Weinstein John N. , Strausberg Robert L. , Yao Jun
Published: April 2023

PDF file - 461K, Isoform switch in FGFR1, 3 is not detected in ccRCC, and FGFR2 switch is not found in breast cancer
Supplementary Figure 2 from Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas
Authors: Zhao Qi , Caballero Otavia L. , Davis Ian D. , Jonasch Eric , Tamboli Pheroze , Yung W.K. Alfred , Weinstein John N. , Strausberg Robert L. , Yao Jun
Published: April 2023

PDF file - 318K, Validation of FGFR2-IIIc isoform switch in ccRCC tumor samples and cell lines by PCR sequencing
Supplementary Table S7 from Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor–Positive Breast Cancer and Their Relationship with Antiproliferative Response
Authors: Gao Qiong , Patani Neill , Dunbier Anita K. , Ghazoui Zara , Zvelebil Marketa , Martin Lesley-Ann , Dowsett Mitch
Published: April 2023

Spearman Rank Correlation Matrix (rho and p-value) of pre-treatment of Gene Module Scores and log2(Ki67pre) Protein Expression. A: Including Proliferation-Associated Genes B: Excluding Proliferation-Associated Genes.
Supplementary Table S10 from Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor–Positive Breast Cancer and Their Relationship with Antiproliferative Response
Authors: Gao Qiong , Patani Neill , Dunbier Anita K. , Ghazoui Zara , Zvelebil Marketa , Martin Lesley-Ann , Dowsett Mitch
Published: April 2023

Spearman Rank Correlation Matrix (rho and p-value) of post-treatment of Gene Module Scores and log2(Ki67post) Protein Expression. A: Including Proliferation-Associated Genes. B: Excluding Proliferation-Associated Genes.
Supplementary Figure S1 from Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor–Positive Breast Cancer and Their Relationship with Antiproliferative Response
Authors: Gao Qiong , Patani Neill , Dunbier Anita K. , Ghazoui Zara , Zvelebil Marketa , Martin Lesley-Ann , Dowsett Mitch
Published: April 2023

CONSORT diagram showing the criteria for selection of patients samples.
Supplementary Figure 4 from RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
Authors: Rampias T. , Giagini A. , Siolos S. , Matsuzaki H. , Sasaki C. , Scorilas A. , Psyrri A.
Published: April 2023

PDF file - 108KB, Oncogenic HRAS effect on phospho-AKT levels.
Supplementary Figure 7 from Synergistic Antitumor Activity of Cetuximab and Namitecan in Human Squamous Cell Carcinoma Models Relies on Cooperative Inhibition of EGFR Expression and Depends on High EGFR Gene Copy Number
Authors: De Cesare Michelandrea , Lauricella Calogero , Veronese Silvio Marco , Cominetti Denis , Pisano Claudio , Zunino Franco , Zaffaroni Nadia , Zuco Valentina
Published: April 2023

PDF file - 1344K, Full-length blots of western blotting figures are presented.
Supplementary Figure 3 from Synergistic Antitumor Activity of Cetuximab and Namitecan in Human Squamous Cell Carcinoma Models Relies on Cooperative Inhibition of EGFR Expression and Depends on High EGFR Gene Copy Number
Authors: De Cesare Michelandrea , Lauricella Calogero , Veronese Silvio Marco , Cominetti Denis , Pisano Claudio , Zunino Franco , Zaffaroni Nadia , Zuco Valentina
Published: April 2023

PDF file - 225K, Expression of EGFR protein in SCC cell lines treated with SN-38 and EGFR mRNA of expression levels in SCC cell lines.
Supplementary Figure 5 from Measles Virus Vaccine–Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells
Authors: Guillerme Jean-Baptiste , Boisgerault Nicolas , Roulois David , Ménager Jérémie , Combredet Chantal , Tangy Frédéric , Fonteneau Jean-François , Gregoire Marc
Published: April 2023

PDF file - 92K, Supplemental Figure 5: shematic of the culture conditions used in the cross-presentation experiments.
Supplementary Figure 6 from Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
Authors: Rexer Brent N. , Ghosh Ritwik , Narasanna Archana , Estrada Mónica Valeria , Chakrabarty Anindita , Song Youngchul , Engelman Jeffrey A. , Arteaga Carlos L.
Published: April 2023

Supplementary Figure 6 - PDF file 293K, Inhibition of P-Akt in xenografts treated with trastuzumab plus/minus cetuximab
Supplementary Figure 4 from Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
Authors: Rexer Brent N. , Ghosh Ritwik , Narasanna Archana , Estrada Mónica Valeria , Chakrabarty Anindita , Song Youngchul , Engelman Jeffrey A. , Arteaga Carlos L.
Published: April 2023

Supplementary Figure 4 - PDF file 152K, T798M mutant expression in as low as 5% of cells is sufficient to confer resistance
Supplementary Movie S3 from A Genetically Engineered Oncolytic Adenovirus Decoys and Lethally Traps Quiescent Cancer Stem–like Cells in S/G2/M Phases
Authors: Yano Shuya , Tazawa Hiroshi , Hashimoto Yuuri , Shirakawa Yasuhiro , Kuroda Shinji , Nishizaki Masahiko , Kishimoto Hiroyuki , Uno Futoshi , Nagasaka Takeshi , Urata Yasuo , Kagawa Shunsuke , Hoffman Robert M. , Fujiwara Toshiyoshi
Published: April 2023

Supplementary Movie S3 - MOV file 6227K, Time-lapse imaging of treatment dynamics of FUCCI-expressing dormant tumor spheres treated with OBP-301 or conventional therapy in three-dimensional culture. Tumor spheres were treated with mock (upper left), OBP-301 (upper right), cisplatin (lower left) or radiation (lower right). Images were acquired every 20 min. The playback speed is 30,240 x real time. Total imaging time = 7days. The cells in G0/ G1, S, or G2/M phases appear red, yellow, or green, respectively
Supplementary Movie S2 from A Genetically Engineered Oncolytic Adenovirus Decoys and Lethally Traps Quiescent Cancer Stem–like Cells in S/G2/M Phases
Authors: Yano Shuya , Tazawa Hiroshi , Hashimoto Yuuri , Shirakawa Yasuhiro , Kuroda Shinji , Nishizaki Masahiko , Kishimoto Hiroyuki , Uno Futoshi , Nagasaka Takeshi , Urata Yasuo , Kagawa Shunsuke , Hoffman Robert M. , Fujiwara Toshiyoshi
Published: April 2023

Supplementary Movie S2 - MOV file 4338K, Time-lapse imaging of FUCCI-expressing tumor spheres cultured in three-dimensional culture without serum (3D culture), or tumor sphere in monolayer culture with serum (monolayer culture). Images were acquired every 20 min. The playback speed is 12,342 x real time. Total imaging time = 48 hours. The cells in G0/ G1, S, or G2/M phases appear red, yellow, or green, respectively.
Supplementary Movie S1 from A Genetically Engineered Oncolytic Adenovirus Decoys and Lethally Traps Quiescent Cancer Stem–like Cells in S/G2/M Phases
Authors: Yano Shuya , Tazawa Hiroshi , Hashimoto Yuuri , Shirakawa Yasuhiro , Kuroda Shinji , Nishizaki Masahiko , Kishimoto Hiroyuki , Uno Futoshi , Nagasaka Takeshi , Urata Yasuo , Kagawa Shunsuke , Hoffman Robert M. , Fujiwara Toshiyoshi
Published: April 2023

Supplementary Movie S1- MOV file 6383K, Time-lapse imaging of FUCCI-expressing CD133+ cells treated with OBP-301 or control on monolayer culture. Images were acquired every 20 min. The playback speed is 10, 800 x real time. Total imaging time = 48 hours. The cells in G0/ G1, S, or G2/M phases appear red, yellow, or green, respectively
Supplementary Information from A Genetically Engineered Oncolytic Adenovirus Decoys and Lethally Traps Quiescent Cancer Stem–like Cells in S/G2/M Phases
Authors: Yano Shuya , Tazawa Hiroshi , Hashimoto Yuuri , Shirakawa Yasuhiro , Kuroda Shinji , Nishizaki Masahiko , Kishimoto Hiroyuki , Uno Futoshi , Nagasaka Takeshi , Urata Yasuo , Kagawa Shunsuke , Hoffman Robert M. , Fujiwara Toshiyoshi
Published: April 2023

- PDF file 1712K, Supplementary Methods Fig. S1. OBP-301 efficiently kills CD133+ cells from MKN7 cells resistant to conventional therapies. Fig. S2. CD133+ CS-like cells can produce CD133+ CS-like cells and CD133- non-CS-like cells. Fig. S3. CD133+ MKN7 cells produce larger colonies than CD133- MKN7 cells in vitro. Fig. S4. CD133+ cells have higher tumorigenicity in nude mice than CD133− cells. Fig. S5. Flow cytometry analysis shows that OBP-301 induces a significant increase in the percentage of both CD133+ CS-like and CD133- non-CS-like cells in S phase. Fig. S6. Expression of CD133 mRNA is associated with the population of CD133+ cells. Fig. S7. OBP-301 reduces the expression of CD133 mRNA. Fig. S8. CD133+ cells show higher expressions of p53, p21 and p27 proteins compared with CD133− cells. Fig. S9. Adenoviral E1A alters cell-cycle related proteins. Fig. S10. Experimental setup in vivo. Fig. S11. Experimental setup for combination therapy of OBP-301 plus cisplatin or paclitaxel in vitro. Fig. S12. The combination therapy of OBP-301 and chemotherapy is more effective than OBP-301 monotherapy on monolayer culture. Fig. S13. OBP-301 reduces the potentiality of stemness in CD133 positive cells. Fig. S14. The combination therapy of OBP-301 and chemotherapy is more effective against larger tumors. Fig. S15. A scheme for oncolytic adenovirus killing quiescent human cancer cells
Supplementary Table 1 from The Immune Signature of CD8+CCR7+ T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC
Authors: Czystowska Malgorzata , Gooding William , Szczepanski Miroslaw J. , Lopez-Abaitero Andres , Ferris Robert L. , Johnson Jonas T. , Whiteside Theresa L.
Published: April 2023

PDF file - 61 KB, Percentages of ANX-binding cells within the peripheral memory (TPM) and terminally differentiating (TTD)subsets in the circulation of HNSCC patients and normal controls
Figure S3 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
Authors: Liu Tao , Hu Wei , Dalton Heather J. , Choi Hyun Jin , Huang Jie , Kang Yu , Pradeep Sunila , Miyake Takahito , Song Jian H. , Wen Yunfei , Lu Chunhua , Pecot Chad V. , Bottsford-Miller Justin , Zand Behrouz , Jennings Nicholas B. , Ivan Cristina , Gallick Gary E. , Baggerly Keith A. , Hangauer David G. , Coleman Robert L. , Frumovitz Michael , Sood Anil K.
Published: April 2023

PDF file 162K, Figure S3. (A) MTT assay results showing the cytotoxicity of KX-01 at various concentrations in clear ovarian carcinoma cells. Cell viability was calculated as the number of cells surviving relative to the number of cells surviving in the control group. IC50 indicates median inhibitory rate. (B) Western blot results showing that the caspase pathway was activated to generate cleaved PARP. Total extracts from RMUG-S and RMUG-L cells treated with 100nM KX-01 for the indicated times were analyzed using the anti-PARP antibody, which detected endogenous levels of full-size (116-kDa) and large-fragment (89-kDa) PARP produced by caspase cleavage. {beta}-actin was used as the loading control. (C, D) Cell migration in RMUG-S and L cells treated with 100 nM KX-01 was analyzed by using a Boyden chamber assay. Data are shown as mean {plus-minus} standard deviation (error bars)
Supplementary Figure 1B from Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials
Authors: Sidhu Roger , Rong Alan , Dahlberg Steve
Published: April 2023

PDF file - 58 KB, First-line phase III trials
Supplementary Figure Legend from Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors
Authors: Zhang Libo , Marrano Paula , Kumar Sushil , Leadley Michael , Elias Evelyn , Thorner Paul , Baruchel Sylvain
Published: April 2023

PDF file - 73K
Supplementary Table 4 from Functional Heterogeneity of Cancer-Associated Fibroblasts from Human Colon Tumors Shows Specific Prognostic Gene Expression Signature
Authors: Herrera Mercedes , Islam Abul B.M.M.K. , Herrera Alberto , Martín Paloma , García Vanesa , Silva Javier , Garcia Jose M. , Salas Clara , Casal Ignacio , de Herreros Antonio García , Bonilla Félix , Peña Cristina
Published: April 2023

XLS file - 271K, CAF signature genes.
Supplementary Figure 3 from Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner
Authors: Palmieri Diane , Duchnowska Renata , Woditschka Stephan , Hua Emily , Qian Yongzhen , Biernat Wojciech , Sosińska-Mielcarek Katarzyna , Gril Brunilde , Stark Andreas M. , Hewitt Stephen M. , Liewehr David J. , Steinberg Seth M. , Jassem Jacek , Steeg Patricia S.
Published: April 2023

PDF file - 96KB, MGMT expression in matched sets of human breast primary tumors and resected brain metastases does not affect overall patient survival.
Supplementary Table S1 from ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602)
Authors: Go Ronald S. , Lee Sandra J. , Shin Donghoon , Callister Steven M. , Jobe Dean A. , Conry Robert M. , Tarhini Ahmad A. , Kirkwood John M.
Published: April 2023

PDF file 80K, Angiogenic factor concentrations in the plasma and urine before and after Peg-IFN treatment
Supplementary Figures from Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)
Authors: Nies Anne T. , Schaeffeler Elke , van der Kuip Heiko , Cascorbi Ingolf , Bruhn Oliver , Kneba Michael , Pott Christiane , Hofmann Ute , Volk Christopher , Hu Shuiying , Baker Sharyn D. , Sparreboom Alex , Ruth Peter , Koepsell Hermann , Schwab Matthias
Published: April 2023

PDF file 79K, Supplementary Figure S1: Uptake of imatinib and OCT1 probe substrate TEA into OCT1-expressing cells and vector-transfected control cells Supplementary Figure S2: Cellular uptake of the OCT1 probe substrate TEA and imatinib into mOct1- or mOct2-expressing HEK293 cells Supplementary Figure S3: Cellular uptake of imatinib into the CML cell lines Meg-01, LAMA-84 and K562 as well as into OCT1-expressing HEK cells and vector-transfected control cells measured after an incubation period of 120 minutes Supplementary Figure S4: Cellular uptake of imatinib into HEK cells expressing variant V408 in comparison to HEK cells expressing reference sequence M408 and vector-transfected control cells measured after an incubation period of 10 minutes Supplementary Figure S5: Knockdown of OCT1 protein expression by the used shRNA
Supplementary Table 6 from Sequential Binary Gene Ratio Tests Define a Novel Molecular Diagnostic Strategy for Malignant Pleural Mesothelioma
Authors: De Rienzo Assunta , Richards William G. , Yeap Beow Y. , Coleman Melissa H. , Sugarbaker Peter E. , Chirieac Lucian R. , Wang Yaoyu E. , Quackenbush John , Jensen Roderick V. , Bueno Raphael
Published: April 2023

XLSX file - 66K, List of the differentially expressed probes for the analysis Epithelioid MPM vs. Sarcomatoid MPM.
Supplementary Figure 4 from PID1 (NYGGF4), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas
Authors: Erdreich-Epstein Anat , Robison Nathan , Ren Xiuhai , Zhou Hong , Xu Jingying , Davidson Tom B. , Schur Mathew , Gilles Floyd H. , Ji Lingyun , Malvar Jemily , Shackleford Gregory M. , Margol Ashley S. , Krieger Mark D. , Judkins Alexander R. , Jones David T.W. , Pfister Stefan M. , Kool Marcel , Sposto Richard , Asgharazadeh Shahab
Published: April 2023

PDF file - 17K, Supplemental Fig 4: PID1 increases the proportion of cells in Sub G0/G1 in CHLA-259 medulloblastoma cells.
Supplementary Figure 1 from PID1 (NYGGF4), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas
Authors: Erdreich-Epstein Anat , Robison Nathan , Ren Xiuhai , Zhou Hong , Xu Jingying , Davidson Tom B. , Schur Mathew , Gilles Floyd H. , Ji Lingyun , Malvar Jemily , Shackleford Gregory M. , Margol Ashley S. , Krieger Mark D. , Judkins Alexander R. , Jones David T.W. , Pfister Stefan M. , Kool Marcel , Sposto Richard , Asgharazadeh Shahab
Published: April 2023

PDF file - 159K, Supplemental Fig 1: PID1 mRNA is lower in less favorable medulloblastomas in two additional independent datasets; PID1 mRNA correlates with rf-PFS when analyzing CHLA medulloblastomas by tertiles.
Supplementary Figure 2 from Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma
Authors: Zheng Ying , McFarland Braden C. , Drygin Denis , Yu Hao , Bellis Susan L. , Kim Hyunsoo , Bredel Markus , Benveniste Etty N.
Published: April 2023

PDF file - 69K, Supplemental Figure 2. Inhibition of CK2 Suppresses IL-6-induced STAT-3 Activation in GBM Cells.
Supplementary Figure 4 from A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
Authors: Kandimalla Raju , Masius Roy , Beukers Willemien , Bangma Chris H. , Orntoft Torben F. , Dyrskjot Lars , van Leeuwen Nikki , Lingsma Hester , van Tilborg Angela A.G. , Zwarthoff Ellen C.
Published: April 2023

PDF file, 27K, Consistency of the multiplex methylation assay.
Supplementary figure from Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
Authors: Iversen Trine Zeeberg , Engell-Noerregaard Lotte , Ellebaek Eva , Andersen Rikke , Larsen Stine Kiaer , Bjoern Jon , Zeyher Claus , Gouttefangeas Cécile , Thomsen Birthe Moerk , Holm Bente , thor Straten Per , Mellemgaard Anders , Andersen Mads Hald , Svane Inge Marie
Published: April 2023

PDF file 132K, Flow cytometry plots
Supplementary Figure 1 from A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
Authors: Kandimalla Raju , Masius Roy , Beukers Willemien , Bangma Chris H. , Orntoft Torben F. , Dyrskjot Lars , van Leeuwen Nikki , Lingsma Hester , van Tilborg Angela A.G. , Zwarthoff Ellen C.
Published: April 2023

PDF file, 58K, Study design.
Supplementary Figure 3 from Inhibition of NF-κB–Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells
Authors: Cosimo Emilio , McCaig Alison M. , Carter-Brzezinski Luke J.M. , Wheadon Helen , Leach Michael T. , Le Ster Karine , Berthou Christian , Durieu Emilie , Oumata Nassima , Galons Hervé , Meijer Laurent , Michie Alison M.
Published: April 2023

PDF file - 56K, CR8 induces CLL cell apoptosis independently of clinical parameters upon treatment at 300 nM.
Supplementary Figure 4 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
Authors: Zaid Tarrik M. , Yeung Tsz-Lun , Thompson Melissa S. , Leung Cecilia S. , Harding Tom , Co Ngai-Na , Schmandt Rosie S. , Kwan Suet-Ying , Rodriguez-Aguay Cristian , Lopez-Berestein Gabriel , Sood Anil K. , Wong Kwong-Kwok , Birrer Michael J. , Mok Samuel C.
Published: April 2023

PDF file - 4313K, Results of immunostaining of ovarian tumor sections obtained from mice
Supplementary Table S2 from The Tumor-Suppressive Function of UNC5D and Its Repressed Expression in Renal Cell Carcinoma
Authors: Lu Dan , Dong Dong , Zhou Yu , Lu Min , Pang Xue-Wen , Li Yan , Tian Xiao-Jun , Zhang Yu , Zhang Jun
Published: April 2023

Supplementary Table S2 - PDF - file 136K, Supplementary Table S2. Relationship of UNC5D methylation, LOH and clinicopathologic characteristics in patients with RCC